Literature DB >> 8751019

Pharmacodynamic modelling of the drug-induced downregulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone.

R E Jonkers1, M C Braat, R P Koopmans, C J van Boxtel.   

Abstract

Changes in beta 2-adrenoceptor function by chronic dosing of beta 2-mimetics and the possible influence of a single dose of prednisone have been studied as changes over time in the concentration-effect relationship of the beta 2-adrenoceptor agonist terbutaline. Hypokalaemia was used as the specific beta 2-adrenoceptor mediated effect. 8 healthy volunteers were given subcutaneous terbutaline 0.01 mg.kg-1 BW on 3 occasions over a 10-day experimental protocol: 1 Control experiment on Day 1; 2 After 7 days of oral terbutaline 5 mg t.i.d. (Day 8); and 3 After 8 days on oral terbutaline and 12 h after prednisone 100 mg orally (Day 10). The time course of the terbutaline concentrations and hypokalaemia was related using a pharmacokinetic-pharmacodynamic model. A sigmoid and a threshold Emax model were used to relate drug concentrations to effects. The oral terbutaline treatment caused a 35% increase in the distribution volume of SC terbutaline. After one week on oral terbutaline the concentration-effect relationship was shifted to the right and was steeper, with a higher EC50 of terbutaline and higher values for the apparent threshold concentration. These observations are compatible with a decrease in receptor numbers after 7 days of terbutaline in a system characterised by the presence of spare receptors. The data after prednisone pretreatment showed an apparent decline in the baseline plasma potassium concentrations that could be included in the Emax model. There was no change in the concentration-effect relationship 12 hours after prednisone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8751019     DOI: 10.1007/bf00192356

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  44 in total

Review 1.  Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure.

Authors:  O E Brodde
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

2.  Subsensitivity to the bronchodilator action of albuterol produced by chronic administration.

Authors:  H S Nelson; D Raine; H C Doner; W C Posey
Journal:  Am Rev Respir Dis       Date:  1977-11

Review 3.  Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase.

Authors:  T K Harden
Journal:  Pharmacol Rev       Date:  1983-03       Impact factor: 25.468

4.  Concentration-dependent effects of prednisolone on lymphocyte subsets and mixed lymphocyte culture in humans.

Authors:  B Oosterhuis; I J ten Berge; P T Schellekens; C J van Boxtel
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

5.  Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects.

Authors:  D P Tashkin; M E Conolly; R I Deutsch; K K Hui; M Littner; P Scarpace; I Abrass
Journal:  Am Rev Respir Dis       Date:  1982-02

6.  Clinical implications of drug-induced desensitization of the beta receptor after continuous oral use of terbutaline.

Authors:  W van den Berg; J G Leferink; J K Fokkens; J Kreukniet; R A Maes; P L Bruynzeel
Journal:  J Allergy Clin Immunol       Date:  1982-05       Impact factor: 10.793

7.  Presence of insulin-renin-aldosterone-potassium interrelationship in normal subjects, disrupted in chronic hemodialysis patients.

Authors:  Z Farfel; A Iaina; H E Eliahou
Journal:  J Clin Endocrinol Metab       Date:  1978-07       Impact factor: 5.958

Review 8.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

9.  beta-adrenergic agonist resistance in normal human airways.

Authors:  S T Holgate; C J Baldwin; A E Tattersfield
Journal:  Lancet       Date:  1977-08-20       Impact factor: 79.321

10.  Pharmacokinetic-pharmacodynamic modeling of terbutaline bronchodilation in asthma.

Authors:  B Oosterhuis; M C Braat; C M Roos; J Wemer; C J Van Boxtel
Journal:  Clin Pharmacol Ther       Date:  1986-10       Impact factor: 6.875

View more
  2 in total

1.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

2.  Prevention by theophylline of beta-2-receptor down regulation in healthy subjects.

Authors:  M G Derks; R P Koopmans; E Oosterhoff; C J Van Boxtel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.